European equities traded in the US as American depositary receipts were higher late Friday morning, rising 1.55% to 1,293.05 on the S&P Europe Select ADR Index. The index is up more than 5% for the week.
From continental Europe, the gainers were led by biopharmaceutical companies Cellectis (CLLS) and argenx (ARGX), which advanced 14% and 5.6% respectively. They were followed by pharmaceutical company Novo Nordisk (NVO) and biopharmaceutical company Genfit (GNFT), which increased 4.6% and 2.5% respectively.
The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and internet advertising firm Criteo (CRTO), which fell 4.3% and 4% respectively. They were followed by furniture manufacturer Natuzzi (NTZ), which dropped 3.5%.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and Amarin (AMRN), which climbed 8.3% and 6.4% respectively. They were followed by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company NuCana (NCNA), which rose 3.8% and 2.7% respectively.
The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Adaptimmune Therapeutics (ADAP), which lost 7% and 2.3% respectively. They were followed by software firm Endava (DAVA) and cruise line operator Carnival (CUK), which were down 2.1% each.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。